We aim to usher in a new age of functional cures for Friedreich’s ataxia (FA) patients with clinically-validated p38 MAP Kinase inhibitors and other safe small molecules. We will also establish leadership in the budding field of epigenetic therapy by developing a novel platform to cure FA, Fragile-X syndrome, Alzheimer’s, certain cancers, and other serious conditions sharing the DNA repeat expansion mechanism. We seek to break frontiers as done in Cystic Fibrosis through scientific leaps comparable to the rise of mRNA or CRISPR technologies.

‘Chief of Staff’ to the SVP and Head of Haematology R&D group, developing 5 and growing number of assets for a score of indications in blood cancer; help manage a rapidly growing team of >150 people and ~$250M budget located around the globe; accountable for the development and administration for effective functioning of the Haematology Leadership Team(LT); provide direct support for strategic and high priority initiatives, driving operational excellence, owning process improvements, optimizing strategy, and building positive relationships internally and externally; lead communications andculture drive for team cohesion and high-performance; establish, set agenda, and convene decision making bodies such as LT meetings; oversee critical resourcing issues such as budgeting and recruitment, handle day-to-day operational tasks such as project tracking; collaborate across AstraZeneca to ensure system compliance and capability development

Developed outcome-based reimbursement models for Saphnelo, a novel biologics treatment for systemic lupus erythematosus; responsible for all brand-specific deliverables related to evidence-based strategies and tactics for innovative reimbursement and payment models at key payers within the U.S. business, as well as value-based agreements (e.g., outcomes-based contracts) and value-based pricing models

Appointed by the Governor of Virginia and serve as a Member, Board for the Blind and Vision Impaired, to support educational initiatives for students and vocational training for adults; managed $6M USD endowment fund

R&D-focused oncology biotech with ~$2 billion annual revenue and ~$15 billion in market cap, leading targeted- and immuno-therapy innovations.Acting as a ‘chief of staff’ reporting to CEO, responsible for day-to-day operation of the firm; coordinated and managed key decision making processes; support Board of Directors meetings; helped implement strategic initiatives; staff public policy engagements by executives; provided healthcare policy, pricing, and market access insights into corporate and R&D strategy; assisted licensing deal making for clinical co-development and commercial rights in international markets.

The Night Ministry connects with Chicago's vulnerable youth and adults through our street outreach, youth shelter and supportive services, and our mobile health outreach bus. We provide basic resources, free healthcare, housing and supportive services for youth, referrals to other agencies for specific resources, in a welcoming and non-judgmental environment.

Managed the Fortune 500 company as a strategic assistant to senior executives to run day-to-day operation; helped spin off a 6-billion-dollar biotech company; led crucial projects such as strategic planning to lay the groundwork for revenue growth and higher valuation; integrated the organization throughout the pharma value chain from a pre-clinical research to drug reimbursement for coordinated decision making.Healthcare Policy Lead, US Patient and Innovation Policy team (2015-2016)- Explored innovative business models for financing curative treatments (e.g., gene therapy) that informed future reimbursement strategy and kick-started conversation with payer-side thought leaders- Analyzed government policy (e.g., biosimilars naming guideline), and helped translate into business strategy that enabled consistent policy advocacy approach- Helped shape public payer coverage and reimbursement environment for marketed and pipeline products; secured payment from public payers (e.g., Medicare)Chief of Staff to the Head of Emerging Therapies and Market Development (2012-2015)- Inculcated customer-centered perspectives throughout the value chains from R&D investment to market access strategy; implemented new processes such as stage-gate reviews across functional teams in R&D, policy, and patient access, which were key steps to pivot Baxalta from a manufacturing powerhouse to a pipeline-oriented biotech firm- Spearheaded strategic planning to understand and expand growth potential, an essential initiative for the launch of Baxalta- Assumed a surrogate management role as needed; served as a counsel and trusted advisor to senior executives; ensured timely and quality delivery of dossiers for key executive committees

Served Fortune 100 corporations, government institutions, with a focus on technology-enabled growth and business development in the pharmaceutical sector. Managed independent work streams including; leading problem solving, interviewing experts, synthesizing findings, briefing team leaders with actionable insights, recommending solutions, and planning implementation. Technology-enabled growth strategies • Devised growth strategy for an EVP of a major pharmaceutical company to augment their ability to analyze and react to post-market clinical data• Developed a blueprint for an FDA Director to incentivize manufacturers to enhance the quality of medical devices Business development• Advised a VP of a key drug distributor to determine optimal bidding prices for supply contracts with an integrated government health system • Prioritized business growth ideas for a SVP of a leading CNS drug company against risk, revenue size, and other measures; built business cases for high priority initiatives

A public company (AMEX:RNN) that develops innovative drugs in oncology and the central nervous system Drug research and development • Worked with CEO/Founder to scan research trends and uncover new drug targets/compounds• Managed CROs to conduct pre-clinical research on drug candidates to combat depression and Parkinson’s disease• Earned over $800K through a federal grant from the Patient Protection and Affordable Care Act• Published a peer-reviewer research article; “Clavulanic acid protects neurons in pharmacological models of neurodegenerative diseases,” Huh YB, Ju MS, Park HB, Han SJ, Bang YM, Ferris CF, Koppell GA, King JA, Kim ML, Kim DJ, Ahn CH, Oh MS, Drug Development Research. 2010;71(6):351-357 Business development• Prepared oral and written presentation materials for CEO to explain drug development programs to investors